ReviewNanomedicine (London, England)2025
Emerging nanoparticles that target and eliminate cancer stem cells.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cancer stem cells (CSCs), a distinct subpopulation within tumors possessing self-renewal and multilineage differentiation capacities, represent the pivotal drivers of therapeutic resistance, tumor recurrence, and metastatic dissemination. The inherent heterogeneity and drug resilience of CSCs render conventional chemotherapy and radiotherapy largely ineffective against this population despite their ability to eliminate bulk tumor cells, ultimately limiting treatment outcomes. In recent years, nanoparticles (NPs) have emerged as promising therapeutic platforms for CSCs-targeted intervention due to their unique physicochemical properties and multifunctional capabilities. This review systematically summarizes recent advances in utilizing organic (liposomes, polymeric nanoparticles), inorganic (gold, silica), and biologically derived (extracellular vesicles, cell membrane-coated NPs) NPs for CSCs eradication. These nanoplatforms achieve active CSCs targeting and elimination through surface modification with CSCs-specific markers, pathway-targeting molecules, or regulators of CSCs biological properties. Although significant progress has been made in nanoparticle-mediated anti-CSCs therapy, critical challenges remain in targeting efficiency, scalable manufacturing, and comprehensive safety evaluation. The continued evolution of drug delivery systems (DDSs) coupled with future breakthroughs in drug delivery vehicles will undoubtedly lead to greater advances in CSCs-targeted DDSs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.